Conventional chemotherapy with DNA-damaging agents has helped countless cancer patients become cancer survivors. This successful outcome is sometimes accompanied by long-term side effects, however. In young female patients, for example, the alkylating agent cyclophosphamide can compromise fertility. This occurs because the drug causes inappropriate activation of ovarian follicular development, thereby exposing oocytes to its DNA-damaging effects. Studying a mouse model, Goldman et al. showed that ovarian function and fertility are preserved when cyclophosphamide is coadministered with drugs called mTORC1/2 inhibitors, which suppress a signaling pathway required for follicular activation. mTORC1/2 inhibitors are already clinically approved for other purposes, including treatment of certain forms of breast cancer, and may merit exploration as a fertility-preserving strategy in female cancer patients.
Paula A. Kiberstis
Want To Publish your Group Article?
Click HERE to send us your group Article for publishing on our website.
- alzheimer Alzheimers Disease animal model antibiotic resistance antibiotics Bacteria Brain breast cancer cancer cell-signaling clinical trials CRISPR diabetes disease/medicine DNA drug drug research Gene Expression general health Gene therapy Genetics genetics & genomics Genomics HIV immunology immunotherapy infectious disease Malaria microbiology microbiome mutation neuroscience new therapy obesity Parkinson's disease stem cells T cells techniques therapy treatment tumor vaccine virology virus Zika virus